-
Neuralstem receives FDA nod to advance MDD compound to Phase Ib
The Wall Street Journal, December 28, 2011
The US Food and Drug Administration (FDA) has given approval to Neuralstem to advance its novel neuroregenerative compound, NSI-189, to Phase Ib in its ongoing clinical trial as a treatment of major depressive disorder (MDD).
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.